Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

3102 ARTÍCULOS , VIENDO DEL 2416 AL 2430

Complex I: inhibitors, inhibition and neurodegeneration

Schapira AH.

Exp Neurol. 2010 Aug;224(2):331-5. doi: 10.1016/j.expneurol.2010.03.028. Epub 2010 Apr 1.

Genome-wide association studies and infectious disease

Bowcock AM.

Crit Rev Immunol. 2010;30(3):305-9. doi: 10.1615/critrevimmunol.v30.i3.80.

Cell loss in the motor and cingulate cortex correlates with symptomatology in Huntington's disease

Thu DC, Oorschot DE, Tippett LJ, Nana AL, Hogg VM, Synek BJ, Luthi-Carter R, Waldvogel HJ, Faull RL.

Brain. 2010 Apr;133(Pt 4):1094-110. doi: 10.1093/brain/awq047.

Electrophysiological measures as potential biomarkers in Huntington's disease: review and future directions

Nguyen L, Bradshaw JL, Stout JC, Croft RJ, Georgiou-Karistianis N.

Brain Res Rev. 2010 Sep;64(1):177-94. doi: 10.1016/j.brainresrev.2010.03.004. Epub 2010 Apr 8.

Inositol trisphosphate receptor Ca2+ release channels in neurological diseases

Foskett JK.

Pflugers Arch. 2010 Jul;460(2):481-94. doi: 10.1007/s00424-010-0826-0. Epub 2010 Apr 10.

Genetic mouse models of Huntington's disease: focus on electrophysiological mechanisms

Cepeda C, Cummings DM, André VM, Holley SM, Levine MS.

ASN Neuro. 2010 Apr 7;2(2):e00033. doi: 10.1042/AN20090058.

The transition metals copper and iron in neurodegenerative diseases

Rivera-Mancía S, Pérez-Neri I, Ríos C, Tristán-López L, Rivera-Espinosa L, Montes S.

Chem Biol Interact. 2010 Jul 30;186(2):184-99. doi: 10.1016/j.cbi.2010.04.010. Epub 2010 May 14.

Cystamine and intrabody co-treatment confers additional benefits in a fly model of Huntington's disease

Bortvedt SF, McLear JA, Messer A, Ahern-Rindell AJ, Wolfgang WJ.

Neurobiol Dis. 2010 Oct;40(1):130-4. doi: 10.1016/j.nbd.2010.04.007. Epub 2010 Apr 24.

Strategies for the inhibition of protein aggregation in human diseases

Bartolini M, Andrisano V.

Chembiochem. 2010 May 17;11(8):1018-35. doi: 10.1002/cbic.200900666.

Nature and cause of mitochondrial dysfunction in Huntington's disease: focusing on huntingtin and the striatum

Oliveira JM.

J Neurochem. 2010 Jul;114(1):1-12. doi: 10.1111/j.1471-4159.2010.06741.x. Epub 2010 Apr 9.

Automatic robust neurite detection and morphological analysis of neuronal cell cultures in high-content screening

Wu C, Schulte J, Sepp KJ, Littleton JT, Hong P.

Neuroinformatics. 2010 Jun;8(2):83-100. doi: 10.1007/s12021-010-9067-9.

Dopamine and glutamate in Huntington's disease: A balancing act

André VM, Cepeda C, Levine MS.

CNS Neurosci Ther. 2010 Jun;16(3):163-78. doi: 10.1111/j.1755-5949.2010.00134.x. Epub 2010 Apr 8.

Antiphospholipid syndrome and central nervous system

Mayer M, Cerovec M, Rados M, Cikes N.

Clin Neurol Neurosurg. 2010 Sep;112(7):602-8. doi: 10.1016/j.clineuro.2010.03.023. Epub 2010 Apr 22.

Huntington's disease: progress toward effective disease-modifying treatments and a cure

Johnson CD, Davidson BL.

Hum Mol Genet. 2010 Apr 15;19(R1):R98-R102. doi: 10.1093/hmg/ddq148. Epub 2010 Apr 26.

Reactive oxygen species: stuck in the middle of neurodegeneration

Patten DA, Germain M, Kelly MA, Slack RS.

J Alzheimers Dis. 2010;20 Suppl 2:S357-67. doi: 10.3233/JAD-2010-100498.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias